AstraZeneca PLC · LSE:AZN
AstraZeneca — Investor Presentation (January 2019)
25 slides from AstraZeneca's investor presentation, January 2019
Slide 1: A focused biopharmaceutical company
A focused biopharmaceutical company General presentation for investors and analysts January 2019
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, pe
Slide 3: Strategic priorities
Strategic priorities Achieve 1 Return 2 Be a great 3 scientific to growth place to work leadership 3
Slide 4: New Cambridge, UK R&D centre and HQ
New Cambridge, UK R&D centre and HQ Scientific collaborations key driver behind move 4
Slide 5: Focused strategy: three therapy areas
Focused strategy Three therapy areas Cardiovascular, Oncology Respiratory Renal & Metabolism Commitment to further focus the portfolio 5
Slide 6: Late-stage pipeline news flow
Late-stage pipeline news flow Significant news flow supports sustainable growth Lynparza Fasenra Lynparza Imfinzi Lynparza Imfinzi Lynparza Tagrisso Lumoxiti breast cancer severe asthma ovarian cancer 2L lung cancer SIII breast cancer lung cancer SIII ovarian cancer 2L lung cancer 1L HCL5 3L approva
Slide 7: Late-stage pipeline and key lifecycle medicines
Late-stage pipeline and key lifecycle medicines Significant opportunities exist in all three therapy areas Cardiovascular, Oncology Respiratory Renal & Metabolism Tagrisso1, 2 roxadustat2 PT010 lung cancer anaemia COPD Imfinzi1, 2 tezepelumab multiple cancers severe asthma Lynparza1, 2 multiple canc
Slide 8: Full pipeline of new medicines (NMEs)
Full pipeline of new medicines (NMEs) Phase I Phase II Phase III 30 New Molecular Entities 27 New Molecular Entities 6 New Molecular Entities Small molecule Large molecule Small molecule Large molecule Small molecule Large molecule AZD0156 Imfinzi#+monalizumab# adavosertib#+chemotherapy AZD8601# Imf
Slide 9: Late-stage pipeline news flow 2019 & 2020
Late-stage pipeline news flow 2019 & 2020 Unlocking and realising potential of new medicine H1 2019 H2 2019 2020 Regulatory Lynparza - breast cancer (EU) Lynparza - ovarian cancer 1L (EU, JP, CN) PT010 - COPD (CN) Tagrisso - lung cancer 1L (CN) decision roxadustat - anaemia (CN) (Q4) Forxiga - type-
Slide 10: 2018: return to sales growth on track
2018: return to sales growth on track Product sales reached the inflection point Unchanged 2018 expectations Medicines important for - Q4 2017 a tough comparison product sales in 2018 Lynparza Tagrisso Imfinzi ongoing launch of tablet in ongoing launch in ongoing launch in ovarian and breast cancer
Slide 11: Product sales: growth across all main therapy areas
Product sales: growth across all main therapy areas Oncology, New CVRM and China all performed very strongly Q3 2018 % product YTD 2018 % product % change % change $m sales $m sales Product sales 5,266 9 100 15,281 2 100 Oncology 1,597 57 30 4,261 44 28 New CVRM 1,027 19 20 2,901 12 19 Respiratory 1
Slide 12: Strategic value-creation framework
Strategic value-creation framework R&D productivity & focus drive decisions Externalisation1 (milestones/royalty) Accelerate/enhance value; or new medicines outside focus Focus on three Product Sales R&D productivity main therapy (Including Growth Platforms) areas ‘Following the science’ Oncology Ot
Slide 13: Emerging Markets: geographic platform for growth
Emerging Markets Geographic platform for growth China 15% of Europe Product Sales US 24% of Product Sales Japan 31% of 11% of Product Product Sales Sales Emerging Rest of Markets World (ex-China) Established 16% of (ex-Japan) Product Sales 4% of 2017 Product Sales as reported. Product Sales 13
Slide 14: Emerging Markets: primary care key to success
Emerging Markets Primary care key to success 51% 32% Asia 68% $70-90bn growth 49% North America 15% Europe $185-215bn $42-49bn growth 85% growth 9% 6% AFME 91% $15-20bn Specialty care Latin growth America Primary care $20-25bn growth 94% 40% World 60% $305-335bn growth Share of absolute growth 2016-
Slide 15: Emerging Markets: specialty care a large growth opportunity
Emerging Markets With specialty care a large growth opportunity 24% 36% Europe 23% US 76% EMs 64% 77% 36% Est. RoW 64% Primary care Specialty care Product sales, YTD 2018. 15
Slide 16: Core Profit & Loss
Core Profit & Loss YTD 2018 % total Q3 2018 % total % change % change $m revenue $m revenue Total revenue 15,673 (8) 100 5,340 (13) 100 - Product sales 15,281 2 97 5,266 9 99 - Externalisation revenue 392 (81) 3 74 (95) 1 Gross margin 79.8% (2) pp - 79.4% (0) pp - Operating expenses1 10,253 2 65 3,3
Slide 17: Debt maturity profile and credit ratings
Debt maturity profile and credit ratings Debt maturity profile at 31 December 20171 3,000 2,500 Weighted average maturity: 10 years 2,000 1,500 $m 1,000 500 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Series5 Series4 Series3 Series2 Series1 Moody’s: A3 | Negative outlook Standard & Poor’s: BBB+ |
Slide 18: Sustainability
Sustainability As a company built on delivering positive health outcomes, sustainability underpins everything AstraZeneca does • As we strive to reach 200 million patients by 2025, we are evolving our approach and in 2017 rolled out a roadmap that further embedded sustainability into the Company’s D
Slide 19: Great place to work: discovery, development and commercial structure
Great place to work Discovery, development and commercial structure Late-stage Discovery and early development development Commercial Innovative Medicines and Early Development Biotech Unit (AstraZeneca Research Global and Early Development) Global Portfolio Internal and Collaborations and Medicines
Slide 20: Great place to work
Great place to work Gothenburg, Sweden Cambridge, UK Gaithersburg, US Strategic R&D Centre Headquarters Strategic R&D Centre 20
Slide 21: Great place to work: realising company vision
Great place to work Realising company vision 1. A passion for people 2. Strong, supportive, development leadership at all levels 6. Access to medicines Values and 3. Flawless technology & social responsibility Purpose and ways of working 5. Environmental 4. Energising sites and sustainability workpl
Slide 22: Great place to work: external recognitions
Great place to work External recognitions 22
Slide 23: AstraZeneca has returned to growth
AstraZeneca has returned to growth Significant inflection point in product sales • Financials improved • Sales returned to growth – Very strong launches continued; reduced impact of Crestor EU/Japan and divestments • Total revenue impacted by lower externalisation in the quarter • Core operating exp
Slide 24: Investor Relations
Investor Relations Thomas Kudsk Larsen Nick Stone Jen Kretzmann thomas.larsen@astrazeneca.com nick.stone@astrazeneca.com jennifer.kretzmann@astrazeneca.com T: +44 20 3749 5712 T: +44 20 3749 5716 T: +44 20 3749 5824 M: +44 7818 524185 M: +44 7717 618834 M: +44 7469 408333 Henry Wheeler Josie Afolabi
Slide 25: Use of AstraZeneca webcast, conference call and presentation slides
Use of AstraZeneca webcast, conference call and presentation slides The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca Materials’) are for your personal, non- commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make availab